What is Mesoblast?
Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast is a biopharmaceutical company dedicated to the development and commercialization of innovative allogeneic cellular medicines. The company utilizes a proprietary technology platform to address significant unmet medical needs in areas such as spine orthopedic disorders, oncology, hematology, and inflammatory conditions. By focusing on off-the-shelf cell therapies, Mesoblast aims to transform the standard of care for patients suffering from chronic and life-threatening diseases, positioning itself as a critical player in the evolving landscape of advanced biological therapeutics.
How much funding has Mesoblast raised?
Mesoblast has raised a total of $744.3M across 8 funding rounds:
Stock Offering
$68.3M
Share Placement
$40M
Debt
$75M
Share Placement
$51M
Share Placement
$90M
Corporate Investment
$110M
Share Placement
$260M
Stock/Share Issuance
$50M
Stock Issuance/Offering (2015): $68.3M with participation from Undisclosed
Share Placement (2017): $40M led by Undisclosed
Debt (2018): $75M supported by Hercules Capital
Share Placement (2019): $51M featuring Undisclosed
Share Placement (2020): $90M backed by Undisclosed
Corporate Investment (2021): $110M with participation from Surgcenter
Share Placement (2025): $260M, investors not publicly disclosed
Stock/Share Issuance (2025): $50M, investors not publicly disclosed
Key Investors in Mesoblast
Hercules Capital
Hercules Capital is a specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries.
Surgcenter
Surgcenter is a healthcare organization that partners with physicians to develop and operate ambulatory surgery centers, providing strategic capital and operational expertise to medical facilities.
Undisclosed Investors
What's next for Mesoblast?
With the recent infusion of $50M, Mesoblast is strategically positioned to advance its core clinical assets through the final stages of regulatory approval. The company is expected to prioritize the scaling of its manufacturing capabilities to meet anticipated commercial demand while simultaneously pursuing strategic partnerships to broaden its therapeutic reach. As the firm transitions into a more mature commercial phase, the focus will likely shift toward optimizing operational efficiencies and securing long-term market access for its flagship cellular products. This capital deployment strategy is designed to maximize shareholder value while delivering transformative medical solutions to patients worldwide.
See full Mesoblast company page
